about
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementEsters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma CellsNeovascular niche for human myeloma cells in immunodeficient mouse boneRoutine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.Salvage therapy with single agent bendamustine for recurrent glioblastoma.Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studySalvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical designSevere Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioPhase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDCarfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoA DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.Bendamustine in patients with relapsed or refractory multiple myeloma.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsA novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells.Bendamustine for treatment of chronic lymphocytic leukemiaTherapy of newly diagnosed follicular lymphoma.Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.SLC22 transporter family proteins as targets for cytostatic uptake into tumor cells.Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.Emerging drugs for Waldenström's macroglobulinemia.Front-line therapy for chronic lymphocytic leukemia.Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.
P2860
Q27002428-FF241923-6FE2-4F49-B898-D74F94C444AEQ28552720-998EC03D-9F37-4371-A81D-F7261FC86A60Q28732210-C0915BAC-A704-43B4-907B-273FF460DE53Q33394853-EF07BB49-B6B4-4330-8D71-139182E510CEQ33395579-A50135E1-794D-47EF-8B4A-FFE354433E5BQ33404348-9DC636DA-6B82-4C64-81B7-B0FC23C99961Q33405428-C95B3DB6-79A5-4B63-91C4-1B9F3A89D5A4Q33406164-12FE8C31-172D-4D7B-9454-1B7B8B8FC538Q33409872-55AC7A18-5F01-4E9F-8454-CDE040B9EB99Q33410756-974C533E-CA0F-46AF-985F-0A09841F8CCFQ33413834-46F30580-F9A5-495F-83C4-87111024E8F4Q33434137-174FE0EB-33C8-4B23-A00E-C8E4255222EAQ33439379-1FCDFCD6-FAC9-4264-81D6-AF49D444D239Q33690142-14C39C8E-5C7A-4284-B655-59D57F1D50FFQ33730841-FF5ABD17-C782-4103-9F29-66828A0B3DE6Q33749652-5CD4BE2E-BAFA-4476-A21A-EADF1F417A24Q33824350-A27B9430-B362-4967-962E-95605A78A2B1Q33877999-EC418B7A-108E-4E9A-91FC-00A07A821CE5Q33934665-1815CE4C-AF9E-4C5C-A10B-A572E98A4299Q34181244-1B736005-CFD5-4EF1-959A-B04B3E8CC4DAQ34202277-18987D49-AA0F-4194-B78A-6117B6AF67F0Q34498655-5A71593B-9268-4854-B59C-11A1246E53EDQ34557179-9F82FAB9-6277-49F1-94FB-7E1363F109B0Q34660110-EC6F8584-D0DB-4A0A-AD38-6D4790F89268Q35206717-B56CCF77-BB42-4E33-8FB1-7EE8B5F0949CQ35483796-52C16C2F-EC45-439A-8211-C6CB5E5BE0CCQ35958553-6945E44D-1570-41EB-84F0-BB2E5B47E813Q36293814-752FEAAC-35BB-4D04-ACD2-673A35C4FD91Q36299600-F1537C3D-2028-4125-A314-87CE5920BD35Q36305762-63723C95-6E54-4CC3-9786-6B5C5EAF2425Q36457298-9D06CE11-A044-480A-BBD7-FBE89B5A7F03Q36883352-9480BFE3-5326-4227-82C8-7CFA95983992Q37376245-C7BD94B5-B211-41B1-818B-9BD68C2AAC97Q37480786-E7AE381E-30D1-4963-AA7F-F137F1A296B2Q37824862-B46A11F2-D9DF-4AE0-8714-8686A72B4FC6Q37844139-23B06DCC-CB86-4970-B79D-D6395CAE5037Q37847176-4AFE9EB3-FFAB-467D-827B-FF0027081946Q37964914-F79E8EEF-95FD-4C06-A845-F2C198AAAFD8Q38040846-A0ADE61C-B45D-4700-A792-2E1DBD1E67B5Q38139989-A35ADFC9-1752-44FC-9159-3B4A86C2B617
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bendamustine: rebirth of an old drug.
@ast
Bendamustine: rebirth of an old drug.
@en
Bendamustine: rebirth of an old drug.
@nl
type
label
Bendamustine: rebirth of an old drug.
@ast
Bendamustine: rebirth of an old drug.
@en
Bendamustine: rebirth of an old drug.
@nl
prefLabel
Bendamustine: rebirth of an old drug.
@ast
Bendamustine: rebirth of an old drug.
@en
Bendamustine: rebirth of an old drug.
@nl
P356
P1476
Bendamustine: rebirth of an old drug.
@en
P2093
Bruce D Cheson
Mathias J Rummel
P304
P356
10.1200/JCO.2008.18.7252
P407
P577
2009-02-17T00:00:00Z